New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - erlotinib hydrochloride 109.28mg equivalent to erlotinib 100mg - film coated tablet - 100 mg - active: erlotinib hydrochloride 109.28mg equivalent to erlotinib 100mg excipient: colloidal silicon dioxide lactose microcrystalline cellulose opadry white 03f180011 purified water sodium laurilsulfate sodium starch glycolate sodium stearyl fumarate - · erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - erlotinib hydrochloride 163.93mg equivalent to erlotinib 150mg - film coated tablet - 150 mg - active: erlotinib hydrochloride 163.93mg equivalent to erlotinib 150mg excipient: colloidal silicon dioxide lactose microcrystalline cellulose opadry white 03f180011 purified water sodium laurilsulfate sodium starch glycolate sodium stearyl fumarate - · erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg - film coated tablet - 25 mg - active: erlotinib hydrochloride 27.32mg equivalent to erlotinib 25mg excipient: colloidal silicon dioxide lactose microcrystalline cellulose opadry white 03f180011 purified water sodium laurilsulfate sodium starch glycolate sodium stearyl fumarate - · erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg; erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg - film coated tablet - 100 mg - active: erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opacode grey s-1-27645 opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate active: erlotinib hydrochloride 109.29mg equivalent to erlotinib 100 mg excipient: hyprolose hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate titanium dioxide - · tarceva is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · tarceva is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg; erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg; erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg; erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg - film coated tablet - 150 mg - active: erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opacode brown s-8-26595 opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate active: erlotinib hydrochloride 163.93mg equivalent to erlotinib 150 mg excipient: hyprolose hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate titanium dioxide - · tarceva is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · tarceva is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg.; erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg.; erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg.; erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg. - film coated tablet - 25 mg - active: erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg. erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg. erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg. excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opacode yellow s-1-22970 opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate active: erlotinib hydrochloride 27.32mg equivalent to erlotinib 25 mg. excipient: hyprolose hypromellose lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose opadry white y-5-7068 sodium laurilsulfate sodium starch glycolate titanium dioxide - · tarceva is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. · tarceva is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (nsclc) who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - erlotinib hydrochloride 109.267mg equivalent to erlotinib 100 mg - film coated tablet - 100 mg - active: erlotinib hydrochloride 109.267mg equivalent to erlotinib 100 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white y-5-7068 purified water sodium laurilsulfate sodium starch glycolate - non-small cell lung cancer erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - erlotinib hydrochloride 163.9mg equivalent to erlotinib 150 mg - film coated tablet - 150 mg - active: erlotinib hydrochloride 163.9mg equivalent to erlotinib 150 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white y-5-7068 purified water sodium laurilsulfate sodium starch glycolate - non-small cell lung cancer erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - erlotinib hydrochloride 27.317mg equivalent to erlotinib 25 mg - film coated tablet - 25 mg - active: erlotinib hydrochloride 27.317mg equivalent to erlotinib 25 mg excipient: lactose monohydrate magnesium stearate microcrystalline cellulose opadry white y-5-7068 purified water sodium laurilsulfate sodium starch glycolate - non-small cell lung cancer erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (stage iiib) or metastatic (stage iv) non-small cell lung cancer (nsclc) with activating egfr mutations. erlotinib is also indicated for the treatment of patients with locally advanced or metastatic nsclc who have previously received chemotherapy.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - erlotinib hydrochloride (unii: da87705x9k) (erlotinib - unii:j4t82ndh7e) - erlotinib 100 mg